s6y

Silexion Therapeutics Corp

Nasdaq
SLXN, SLXNW
CIK
2022416
Industry
Biological Products, (No Diagnostic Substances)
Based in
Israel
Incorporated in
Cayman Islands
Fiscal year ends
December 31
SEC filer category
Emerging growth company
Formerly
Biomotion Sciences

Key figures

Fiscal year to Dec 2025 Dec 2024
Operating income −$11.6M−$12.6M
Net income −$11.9M−$16.5M
Diluted EPS $8.96$394.94
Cash from operations −$10.8M−$8.40M
Total assets $7.21M$2.86M
Shareholders’ equity $2.60M−$3.99M

From the company’s annual reports to the SEC. Each year links to its report.

Name Role As of
Hadar Ilan Chairman and CEO, Director
Horenshtein Hadar Mirit CFO and Secretary
Shirvan Mitchell CSO and CDO
Noy Shlomo Director
Abramov Dror Yosef Director
Alon Ruth Director

All 10 · How this list is made

Name Stake As of
Moringa Sponsor, LP 17.7%
Intracoastal Capital, LLC 5%
Lind Global Fund III LP 5%

How this list is made

Financials 11

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-K/A Annual Report for period ending Dec 31, 2025
  4. 10-Q Quarterly Report for period ending Mar 31, 2026
  5. 10-K Annual Report for period ending Dec 31, 2025
  6. 10-Q Quarterly Report for period ending Sep 30, 2025
  7. 10-Q Quarterly Report for period ending Jun 30, 2025
  8. 10-Q Quarterly Report for period ending Mar 31, 2025
  9. 10-K Annual Report for period ending Dec 31, 2024
  10. 10-Q Quarterly Report for period ending Sep 30, 2024

All 11 financials filings

News 87

  1. 8-K Other events
  2. 8-K Financial results
  3. 8-K Change to shareholder rights; Charter or bylaw change; Other events
  4. 8-K Other events
  5. 8-K Charter or bylaw change; Shareholder vote results
  6. 8-K Regulation FD disclosure
  7. 8-K Material agreement; Unregistered share sale; Other events
  8. 8-K Regulation FD disclosure
  9. 8-K Delisting notice
  10. 8-K Shareholder vote results

All 87 news filings

Ownership 53

  1. SCHEDULE 13D/A Major shareholder report
  2. SCHEDULE 13D/A Major shareholder report
  3. SCHEDULE 13G Major shareholder report (passive investor)
  4. SCHEDULE 13G/A Major shareholder report (passive investor)
  5. SCHEDULE 13D/A Major shareholder report
  6. 4 Change in insider ownership
  7. 4 Change in insider ownership
  8. 4 Change in insider ownership
  9. SCHEDULE 13D/A Major shareholder report
  10. SCHEDULE 13G/A Major shareholder report (passive investor)

All 53 ownership filings

Prospectus 56

  1. S-3 Registration statement for specified transactions by certain issuers
  2. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  3. 424B4 Prospectus filed pursuant to Rule 424(b)(4)
  4. S-1/A General form of registration statement for all companies including face-amount certificate companies
  5. S-1 General form of registration statement for all companies including face-amount certificate companies
  6. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  7. S-3 Registration statement for specified transactions by certain issuers
  8. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  9. DRS Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  10. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

All 56 prospectus filings

Proxies 26

  1. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  2. DEF 14A Definitive proxy statements
  3. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  4. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  5. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  6. DEF 14A Definitive proxy statements
  7. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  8. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  9. DEF 14A Definitive proxy statements
  10. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition

All 26 proxies filings

Other 52

  1. EFFECT Notice of Effectiveness
  2. EFFECT Notice of Effectiveness
  3. EFFECT Notice of Effectiveness
  4. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  5. UPLOAD Letter (PDF)
  6. EFFECT Notice of Effectiveness
  7. EFFECT Notice of Effectiveness
  8. POS AM Post-effective amendment to a registration statement that is not immediately effective upon filing
  9. POS AM Post-effective amendment to a registration statement that is not immediately effective upon filing
  10. EFFECT Notice of Effectiveness

All 52 other filings

Others in Biological Products, (No Diagnostic Substances)

Every company in this industry